In this podcast, we commemorate Bladder Cancer Awareness Month in
May with a special limited series, where we invite a special guest to
discuss and share their expert perspectives within this ever evolving field.
This week, Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer
Center, New York, NY, will be talking about antibody-drug conjugates,
which have made a big impact in the treatment landscape of bladder
cancer and other solid tumors. He will provide his thoughts on the
approval of enfortumab vedotin, managing toxicities, and the future of
ADCs
Create your
podcast in
minutes
It is Free